RNA Analysis Market Research Report Information By Product & Service (Reagents/Consumables, Instrument, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Microarrays, Sequencing and RNA Interference), By Application (Drug Discovery, Clinical Diagnostics, Toxicogenomics and Comparative Transcriptomics), By End User (Pharmaceutical & Biotechnology Company, Hospitals & Diagnostic Centers, Academic & Research Institutes and CROs) And By Region (North America, Europe, Asia-Pacific and Rest Of The World) –Market Forecast Til

Global RNA Analysis Market Overview

As per MRFR analysis, the RNA Analysis Market Size was estimated at 8.19 (USD Billion) in 2024. The RNA Analysis Market Industry is expected to grow from 9.36 (USD Billion) in 2025 to 30.91 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 14.20% during the forecast period (2025 - 2034). The increasing need for personalized medication, drug development and biopharmaceutical research are the primary market drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In May 2024, the life science reagent company RNAConnect officially launched. Its goal is to provide advanced solutions for the exploration of the diversity that exists in RNA sequences and structures,” enhancing research in the RNA field.

In November of 2024, Avidity biosciences'stock peaked after the company disclosed progress on its RNA platform focusing on cardiovascular diseases. The company intends to develop therapies for PLN cardiomyopathy and PRKAG2 syndrome. Laboratory studies provided initial evidence for 80% reductions in the disease-causing proteins in cardiac tissues. This marks a new advance in the delivery of RNA-targeting drugs to non-liver muscles and the heart. It is further supported by a strategic collaboration with Bristol Myers Squibb to scope out ten cardiovascular targets.

In October 2024, Wave Life Sciences reported positive interim results from a mid-stage trial for its Duchenne muscular dystrophy (DMD) treatment. The potential candidate, WVE-N531, is being trialed bi-weekly on children aged between 5-11. After twenty-four weeks, the treatment demonstrated significant dystrophin expression and was well tolerated. The firm expects to hear regulatory guidance on a request for accelerated approval, while a 48-week analysis is anticipated early in 2025.

RNA Analysis Market Trends

• Growing demand for reagents/consumables is driving the market growth.

The consumables and reagents are ready to use, making RNA analysis research and operations easier. The growing prevalence of infectious diseases and cancer is also expected to support the growth of reagents/consumables throughout the projection period, driving the market CAGR. Furthermore, the use of media and reagents in transcriptome studies is increasing, as is the need for high-quality reagents. The reagents/consumables category is growing due to the biotechnology industry's expanded R&D activities, government investment in life science research and the expanding field of integrated omics investigations. Human papillomavirus (HPV) and hepatitis are two viruses that can cause cancer; they represent over 30% of cancer cases in low- and lower-middle-income countries, according to the WHO's February 2022 update. Cancer is one of the leading causes of death globally. In medical specialties and diagnostic care facilities, there is a higher demand for diagnosis due to the increased prevalence of infectious diseases and cancer, which is anticipated to fuel segmental expansion over the study period. The market expansion has also been driven by the participants' launching of new products. In March 2021, for example, PCR Biosystems, a UK-based DNA and RNA analysis expert, introduced a line of Iso Fast BST Polymerase reagents for sensitive, fast and reliable RNA amplification. As a result of these product approvals, the market is expected to increase significantly over the analysis period.

A genetic disease that can be inherited or developed from certain environmental exposures, cancer is one of the most common genetic illnesses that are diagnosed. Prostate cancer led the list of cancer causes for men, while breast cancer led the list for women, according to the American Cancer Society's 2022 update. Also, according to the source above, the largest number of cancer cases, 1,117,640, were reported by individuals 65 years of age and older than by any other age group. RNA sequencing has been employed in numerous facets of cancer research and treatment, offering a useful method for identifying various cancer forms and other uncommon illnesses. Because of the rising prevalence of cancer and other disorders, there is a growing need for RNA analysis technologies, which is driving the market's expansion.

Furthermore, researchers may investigate complex tissues and varied cell populations with scRNA-Seq, uncovering unique cell types, subtypes and states that might be hidden in bulk RNA sequencing investigations. This richer awareness of cellular heterogeneity improves our comprehension of biological systems and disease pathogenesis. scRNA-Seq makes it possible to find and characterize rare cell populations important for development, disease progression and therapy response. Examples of these populations include immunological subsets, circulating tumor cells and stem cells. This has significant ramifications for targeted medicines, prognostics and diagnostics. Thus driving the RNA Analysis market revenue.

RNA Analysis Market Segment Insights

RNA Analysis Product & Service Insights

Based on Product & Service, the RNA Analysis market segmentation includes reagents/consumables, instruments, software and services. In 2023, the reagents/consumables segment dominated the market. Reagents and consumables are in high demand because of the increasing focus on RNA analysis in basic and translational research. RNA extraction kits, reverse transcription kits, PCR reagents and library preparation kits are only a few of the many reagents needed by academic institutions, research labs and biotechnology businesses to carry out RNA sequencing, qPCR, microarray analysis and other RNA analysis procedures.

The services category is anticipated to be the fastest growing. The need for RNA analysis services is predicted to rise in response to expanding government funding for life science research and pharmaceutical industry R&D activity. Numerous businesses actively provide RNA analysis services, such as transcriptome profiling, mRNA sequencing and end-to-end solutions like RNA sample preparation, library creation, sequencing and data analysis. These businesses include Eurofins Scientific, Genewiz and QIAGEN. The market is anticipated to grow in the upcoming years due to the availability of a wide range of services.

RNA Analysis Technology Insights

Based on Technology, the RNA Analysis market segmentation includes polymerase chain reaction (PCR), microarrays, sequencing and RNA interference. In 2023, the polymerase chain reaction (PCR) category generated the most income. Because of its great sensitivity and specificity, polymerase chain reaction (PCR) can accurately detect and quantify RNA targets, such as mRNA transcripts and non-coding RNAs, even at low expression levels. PCR allows for the rapid amplification of RNA targets in hours, facilitating rapid diagnostic and research turnaround times. By enabling real-time amplification kinetics monitoring, techniques like real-time quantitative PCR (qPCR) substantially improve efficiency.

The RNA analysis sequencing segment market is anticipated to grow fastest during the forecast period because of developments in SMRT and next-generation sequencing technologies. The industry is also being driven by the proliferation of businesses offering single-cell RNA sequencing services and the development of bioinformatics techniques. Furthermore, rising scientific awareness and reducing sequencing technology costs will drive the market throughout the estimated period.

Figure 1: RNA Analysis Market, by Technology, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

RNA Analysis Application Insights

Based on application, the RNA analysis market segmentation includes drug discovery, clinical diagnostics, toxicogenomics and comparative transcriptomics. The clinical diagnostics category leads the market. RNA analysis makes identifying cancer-specific gene signatures and molecular subtypes possible, especially when using methods like RNA sequencing and gene expression profiling. Accurate cancer diagnosis, subclassification and patient outcome prediction are made easier with this knowledge, which also influences therapy choices.

The RNA analysis market’s drug discovery segment is anticipated to grow fastest during the projection period. The identification and validation of biomarkers for prognosis, treatment response prediction and illness diagnosis are made possible by RNA analysis. Patient samples such as blood, tissue biopsies, or circulating tumor cells can be transcriptomic profiled to find RNA biomarkers linked to therapy resistance, disease progression and patient outcomes.

RNA Analysis End User Insights

Based on end user, the RNA Analysis market segmentation includes pharmaceutical & biotechnology company, hospitals & diagnostic centers, academic & research institutes and CROs. The hospitals & diagnostic centers category leads the market. RNA analysis is used by hospitals and diagnostic institutes to profile cancer tissues and categorize tumors according to molecular subtypes, patterns of gene expression and oncogenic pathways. In cancer practice, this genetic profiling helps with tumor categorization, patient stratification and targeted therapy selection.

The CROs segment of the RNA Analysis market is predicted to develop at the quickest rate over the projected period. The strategic activities of major market players aid the expansion of the segment. For example, in January 2022, 10x Genomics declared that three top CROs would be added to its 10x Certified Service Provider Network. The CROs and 10x Genomics will collaborate to assist top biopharmaceutical firms looking to leverage the single-cell and spatial technologies of 10x Genomics to speed up drug development and fuel innovative therapeutic discoveries. Azenta Life Sciences, Q2 Solutions and CellCarta are the three CROs selected for the 10x Genomics initiative.

RNA Analysis Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American RNA Analysis market will dominate this market. Owing to the rapid advancement of structure-based medication designs, the growing focus on transcriptomics research and the significant investments made in biopharmaceutical research and development are all responsible for this supremacy. Furthermore, the notable increase in funding dedicated to pharmaceutical research and medication development is a major driver of revenue growth for businesses in this area. An increased market presence results from research and development endeavors coming together to create this dynamic landscape.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil.

Figure 2: RNA ANALYSIS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's RNA Analysis market accounts for the second-largest market share because Europe has a thriving biotechnology and life sciences industry, with top universities, research centers and biotech firms actively engaged in the advancement of RNA analysis. This environment encourages creativity, teamwork and the commercialization of research results. Further, the German RNA Analysis market held the largest market share and the UK RNA Analysis market was the fastest-growing market in the European region.

The Asia-Pacific RNA Analysis Market is expected to grow at the fastest CAGR from 2025 to 2034. The rising levels of corporate and governmental funding promoting biotechnology research throughout the Asia-Pacific region serve as the foundation for this prediction. Particularly in the medical and life sciences fields, Japan has strong financing from both the public and private sectors to encourage the advancement of biotech research. This supportive atmosphere gives researchers the confidence to investigate the field of transcriptomics actively. Moreover, China’s RNA Analysis market held the largest market share and the Indian RNA Analysis market was the fastest-growing market in the Asia-Pacific region.

RNA Analysis Key Market Players & Competitive Insights

The RNA Analysis market will continue to grow due to major companies in the industry making significant R&D investments to extend their Product & Service ranges. Significant market developments include new Product & Service releases, contractual agreements, mergers and acquisitions, greater investments and cooperation with other organizations. Market participants also engage in various strategic actions to broaden their footprint. The RNA Analysis sector must provide affordable Products & Services to grow and thrive in a more cutthroat and dynamic market.

One of the main strategies manufacturers use in the worldwide RNA Analysis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. Some of the biggest medical benefits in recent years have come from the RNA Analysis sector. Major players in the RNA Analysis market, including Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN, Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Promega Corporation, GenXPro GmbH and others, are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc. (Thermo Fisher) supplies tools for medicine, analytical equipment, consumables and reagents, software and services for handling difficult analytical problems in clinical, research and diagnostic labs. It provides answers for synthetic biology, flow cytometry and cellular biology. Products from the company include technologies for molecular biology, genetic sequencing, electron microscopy, protein analysis and mass spectrometry. Serving the environmental, industrial quality and process control sectors, government organizations, academic and research institutions, pharmaceutical and biotech firms and clinical diagnostic labs. Thermo Fisher acquired Phitonex in January 2021 to expand its flow cytometry and imaging multiplexing capabilities for protein and cell analysis research needs. Phitonex expands the company's current portfolio of products for protein and cell analysis.

The life sciences business Eurofins Scientific SE (Eurofins) offers analytical testing services to customers in various industries. The company provides environmental testing, forensic services, geoscience services, food and feed testing, biopharma services, pharma discovery services, pharma early development, pharma central laboratory, biopharma product testing and product testing. Its analytical techniques support assessing biological products and chemicals' safety, identification, composition, origin, authenticity and purity. It uses its knowledge of information technology and logistics to provide various services. Eurofins purchased Beacon Discovery, a CRO focused on drug discovery, in March 2022. Beacon assisted with completely integrated drug discovery initiatives, ranging from pre-clinical candidates to target validation.

Key Companies in the RNA Analysis market include

• Thermo Fisher Scientific


• F. Hoffmann-La Roche Ltd


• Illumina, Inc


• QIAGEN


• Eurofins Scientific


• Merck KGaA


• Bio-Rad Laboratories, Inc.


• Agilent Technologies, Inc


• Promega Corporation


• GenXPro GmbH

RNA Analysis Industry Developments

In November 2024 Dash Bio, a biotech services startup founded by ex-Moderna executives, was incorporated with the objective to quicken the pace of drug development. Self-sufficient Pre-clinical and Clinical Research with the aid of Robotics and AI Dash focuses on enabling drugmakers to analyze the results from clinical trials much faster than it usually takes. This can decrease the time needed to make decisions from months to weeks. So far, the company has gotten $6.5 million during seed funding and expects to serve consumers by early 2025.

In November 2024, United Kingdom health authorities collaborated with Oxford Nanopore Technologies to enhance the detection of hazardous pathogens and provide alerts at the earliest possible moment for a potential pandemic to occur. The initiative, which started at 30 NHS locations, intends to diagnose and manage critical respiratory infections within six hours after a patient sample is taken. This collaboration employs Oxford Nanopore long-read sequencing technology and further develops NHS England's Respiratory Metagenomics program to better surveil for bacterial and viral as well as multidrug-resistant pathogens.

RNA Analysis Market Segmentation

RNA Analysis Product & Service Outlook

• Reagents/Consumables


• Instrument


• Software


• Services

RNA Analysis Technology Outlook

• Polymerase Chain Reaction (PCR)


• Microarrays


• Sequencing


• RNA Interference

RNA Analysis Application Outlook

• Drug Discovery


• Clinical Diagnostics


• Toxicogenomics


• Comparative Transcriptomics

RNA Analysis End User Outlook

• Pharmaceutical & Biotechnology Company


• Hospitals & Diagnostic Centers


• Academic & Research Institutes


• CROs

RNA Analysis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Attribute/Metric	Details
Market Size 2024	8.19 (USD Billion)
Market Size 2025	9.36 (USD Billion)
Market Size 2034	30.91 (USD Billion)
Compound Annual Growth Rate (CAGR)	14.20 % (2025 - 2034)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2034
Historical Data	2020 - 2024
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors and Trends
Segments Covered	Product & Service, Technology, Application, End User and Region
Geographies Covered	North America, Europe, Asia Pacific and the Rest of the World
Countries Covered	The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea and Brazil
Key Companies Profiled	Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Illumina, Inc, QIAGEN, Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc, Promega Corporation and GenXPro GmbH
Key Market Opportunities	Integration with artificial intelligence and machine learning and expansion into point-of-care diagnostics
Key Market Dynamics	Increasing need for personalized medication and drug development and biopharmaceutical research